Share Cancellation
HAI summary · Not investment advice
Hanmi Pharmaceutical, a subsidiary of Hanmi Science, decided to retire 85,316 common treasury shares, with a book value of KRW 28.3 billion, on November 2, 2026.
Cancellation amount
KRW 28.3 billion
Based on the book value of the shares to be retired
Key facts
- Acquisition method
- Treasury shares already acquired
- Cancellation date
- Nov 2, 2026May change following consultation with relevant authorities
- Board resolution date
- Oct 27, 2026
Commentary
AI commentary · Not investment advice
What happened
Hanmi Pharm decided to retire 85,316 common shares of treasury stock it had already acquired. The planned amount is KRW 28.3 billion, and the retirement is scheduled for November 2, 2026. The board resolved on October 27, 2026, and the filing was received the same day.
In the company's terms
The materials list total issued common shares at 12,810,991. The size of this retirement is recorded as 1.0% relative to market capitalization. The shares being retired are treasury stock already held, not newly purchased ones.
What changes for shareholders
The scheduled retirement date is November 2, 2026.
Earlier Share Cancellation filings from this company
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.10.272026.10.27 | Share Cancellation | KRW 9.4 billion · Based on the book value of the shares to be retired |
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist